- Analytical Data Sheet (ADS)
- Bachem App
- Custom Synthesis
- Confidentiality
- Peptide Calculator
- Peptide Content Calculator
- Regulatory Affairs
- Technical Library
- Newsletter
- New Product Alerts
- Peptide Trends November 2020
- Peptide Trends October 2020
- Oligonucleotide Trends September 2020
- Peptide Trends September 2020
- Peptide Trends July 2020
- Peptide Trends June 2020
- Peptide Trends May 2020
- Peptide Trends April 2020
- Peptide Trends March 2020
- Peptide Trends February 2020
- Oligonucleotide Trends January 2020
- Peptide Trends January 2020
- Newsletter Archive
- Webinar
- Glossary & Abbreviations
- FAQ
- Search Function
- General Conditions
PEPTIDE TRENDS MARCH 2015

Meet us at DCAT, New York City, USA, March 16-19, 2015
Bachem is participating in the Drug, Chemical & Associated Technologies Association, Inc. (DCAT) Week. DCAT Week is considered the pharmaceutical industry’s premier event for business development. Pharmaceutical and chemical sourcing professionals, manufacturers, suppliers, distributors, and service providers come together to meet and build relationships.
Bachem is the world´s leading independent manufacturer of peptides used as active pharmaceutical ingredients (APIs) with a range of more than 40 generic products of which more than 25 are peptides. Our generic APIs are used in the field of cancer, diabetes, obesity, fertility and many more.
We would like to invite you to visit us at Suite 40M during DCAT Week 2015 on March 16-19, 2015 at the Waldorf Astoria Hotel, New York, USA.
Our Business Development Executives would be glad to present details of our generic APIs portfolio.
We have the capacity to produce generic peptide APIs in quantities of hundreds of kilograms and small molecules in tens of tons per year. Our GMP manufacturing facilities are located in Switzerland and the United States and are regularly inspected by the FDA and local authorities.
PEPTIDE NEWS FRAGMENTS
We search the Internet for news about peptides in basic research and pharmaceutical development. Here are some highlights from recent week:
Research uncovers potential therapy to prevent arrhythmias, sudden cardiac death after heart attack – PR Newsire
Promising novel target for multiple sclerosis therapy discovered – GEN
Sticky protein hails new approach for treating Parkinson's – EurekAlert!
Nano-sized 'drones' deliver targeted drugs and repair arteries – Medical News Today
The interview: Andre Casagrande, Group Leader generics
PT: Andre,tell us what you do at Bachem?
Andre: I am group leader generics and together with my team we are taking care of the sales activities on our Generic APIs within Europe, MENA and parts of Asia (mainly India).
PT: How long have you been with Bachem and what did you do before?
Andre: I have started my career at Bachem in 2002 directly after college.
PT: What is your academic background/degrees or training?
Andre: My background is commercial and I am holding an EMBA from the University of Applied Sciences of Northwestern, Switzerland.
PT: Last but not least, what do you like to do outside of Bachem?
Andre: I like to run and ski. I do also enjoy cars very much.
PT: Thank you very much, Andre.
LATEST LITERATURE CITINGS

> Staphylococcus aureus-induced clotting of plasma is an immune evasion mechanism for persistence within the fibrin network
> Kinin B1 receptor regulates interactions between neutrophils and endothelial cells by modulating the levels of Mac-1, LFA-1 and intercellular adhesion molecule-1
> A Metalloprotease Secreted by the Type II Secretion System Links Vibrio cholerae with Collagen Bo R. Park, Ryszard A. Zielke, Igor H. Wierzbicki, Kristie C. Mitchell, Jeffrey H. Withey, and Aleksandra E. Sikora |
Peptide Puzzler


How many Peptides are available @ shop.bachem.com ?
A.)333
B.)999
C.)more than 3,000
Rules
Submit the correct answer to puzzle@bachem.com by 12:01 am Los Angeles time on Friday, March 27, 2015 for your chance to win a Bachem football .
Last Month's Winner
Congratulations to Austin McMordie!
Austin has been working at Almac in Northern Ireland for over 15 years. During this time he has held various chemistry positions with Almac’s custom synthesis, radiochemistry and process development groups. His current role as New Opportunities Manager involves the preparation of technical proposals for new chemistry projects.